Please assess the completion status of the following clinical trial:

Trial Title: Study of Adults With Low Growth Hormone Who Survived Childhood Cancer Where Treatment Caused Low Bone Density

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Growth hormone deficiency as a complication of treatment for pediatric malignancy~* Dexa (bone densitometry)with z-scores of \< -1.0 in at least one site~Exclusion Criteria:~* Dexa (bone densitometry)with z-scores \< -1.0 in at least one site~* Subjects \<18 years old~* Pregnant or lactating patients~* Any contraindication for or unwillingness to consider bisphosphonate treatment~* Inability or unwillingness to undergo bone density evaluation~* Other correctable causes of decreased bone mineral density

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Growth Hormone only (Type: ACTIVE_COMPARATOR): No bisphosphonate therapy given, participants will take Vitamin D 400 IU daily for 18 months, as well as calcium carbonate 500 mg twice a day for 18 months.
- Growth Hormone & Bisphosphonate Therapy (Type: EXPERIMENTAL): Bisphosphonate Therapy-Risedronate 35 mg once a week for 18 months, Vitamin D 400 IU daily for 18 months and calcium carbonate 500 mg twice daily for 18 months

Based on this trial design, predict the completion outcome and termination type (if applicable).